These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 30578668)

  • 1. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience.
    Conti A; Peccerillo F; Amerio P; Balato A; Bardazzi F; Bianchi L; Burlando M; Cannavò SP; Chiricozzi A; Dapavo P; De Simone C; Fargnoli MC; Gambardella A; Gisondi P; Malagoli P; Malara G; Mugheddu C; Offidani AM; Piaserico S; Prignano F; Stingeni L; Pellacani G
    Br J Dermatol; 2019 Jun; 180(6):1547-1548. PubMed ID: 30578668
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: A single-center experience.
    Ohata C; Ohyama B; Katayama E; Nakama T
    J Dermatol; 2020 Apr; 47(4):405-408. PubMed ID: 31994229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
    Gordon KB; Leonardi CL; Lebwohl M; Blauvelt A; Cameron GS; Braun D; Erickson J; Heffernan M
    J Am Acad Dermatol; 2014 Dec; 71(6):1176-82. PubMed ID: 25242558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience.
    Sherman S; Solomon Cohen E; Amitay-Laish I; Hodak E; Pavlovsky L
    Acta Derm Venereol; 2019 Jul; 99(9):769-773. PubMed ID: 31017250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies.
    Georgakopoulos JR; Phung M; Ighani A; Yeung J
    J Am Acad Dermatol; 2018 Jul; 79(1):155-157. PubMed ID: 29307635
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.
    Zachariae C; Gordon K; Kimball AB; Lebwohl M; Blauvelt A; Leonardi C; Braun D; McKean-Matthews M; Burge R; Cameron G
    J Am Acad Dermatol; 2018 Aug; 79(2):294-301.e6. PubMed ID: 29653208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.
    Syed YY
    Am J Clin Dermatol; 2017 Feb; 18(1):147-158. PubMed ID: 28138946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
    Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
    J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated safety analysis: Frequency of urinary tract infections in patients with psoriasis treated with ixekizumab.
    Smith SD; Conrad C; Ramharter M; Gottlieb AB; Patel H; Xu W; Riedl E; Schuster C
    J Am Acad Dermatol; 2020 Jul; 83(1):261-263. PubMed ID: 32092375
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis.
    Romiti R; Valenzuela F; Chouela EN; Xu W; Pangallo B; Moriarty SR; Gürbüz S; Riedl E
    Br J Dermatol; 2019 Jul; 181(1):202-203. PubMed ID: 30609008
    [No Abstract]   [Full Text] [Related]  

  • 12. Brodalumab-associated generalized eczematous eruption in a difficult-to-treat psoriasis patient: management without brodalumab withdrawal.
    Danset M; Hacard F; Jaulent C; Nosbaum A; Berard F; Nicolas JF; Goujon C
    Eur J Dermatol; 2020 Dec; 30(6):741-743. PubMed ID: 33337328
    [No Abstract]   [Full Text] [Related]  

  • 13. Effective treatment with guselkumab for psoriatic alopecia as paradoxical reaction.
    Hosokawa Y; Hamada T; Ashida H; Ikeda M
    J Dermatol; 2019 Aug; 46(8):e302-e303. PubMed ID: 30861165
    [No Abstract]   [Full Text] [Related]  

  • 14. Ixekizumab (Taltz)--a second IL-17A inhibitor for psoriasis.
    Med Lett Drugs Ther; 2016 May; 58(1494):59-60. PubMed ID: 27148922
    [No Abstract]   [Full Text] [Related]  

  • 15. Pleural Fluid Eosinophilia: A Possible Adverse Event of Interleukin-17 Inhibition.
    Hayashi W; Osada SI; Toyoshima A; Yamada K; Sudo K; Nakayama K; Manabe M
    Acta Derm Venereol; 2019 Nov; 99(12):1174-1175. PubMed ID: 31502653
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
    Kimura R; Sugita K; Yamamoto O
    Eur J Dermatol; 2020 Dec; 30(6):732-734. PubMed ID: 33237034
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study.
    Gasslitter I; Kirsten N; Augustin M; Torz K; Mrowietz U; Eyerich K; Puig L; Hoetzenecker W; Schütz-Bergmayr M; Weger W; Wolf P; Reider N; Ratzinger G; Papageorgiou K; Meier TO; Maul JT; Anzengruber F; Navarini AA
    Arch Dermatol Res; 2019 Jul; 311(5):421-424. PubMed ID: 30879102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Therapeutic Approaches and Targets for Treatment of Psoriasis.
    Radi G; Campanati A; Diotallevi F; Bianchelli T; Offidani A
    Curr Pharm Biotechnol; 2021; 22(1):7-31. PubMed ID: 32598253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab.
    Blauvelt A; Shi N; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Zhu B; Murage MJ
    J Am Acad Dermatol; 2020 Apr; 82(4):927-935. PubMed ID: 31712178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis.
    Ryan C; Menter A; Guenther L; Blauvelt A; Bissonnette R; Meeuwis K; Sullivan J; Cather JC; Yosipovitch G; Gottlieb AB; Merola JF; Callis Duffin K; Fretzin S; Osuntokun OO; Burge R; Naegeli AN; Yang FE; Lin CY; Todd K; Potts Bleakman A;
    Br J Dermatol; 2018 Oct; 179(4):844-852. PubMed ID: 29747232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.